BCIQ Profiles

Company Profile ReportTarget Profile Report

Refuge: Receptive CAR checkpoints

How Refuge is using CRISPR to suppress checkpoint genes in CAR T cells

Refuge Biotechnologies Inc. aims to make CAR T cells more potent by suppressing their checkpoint genes and is using a form of CRISPR that knocks the genes down instead of out to improve safety.

CEO Bing Wang told BioCentury that like endogenous T cells, CAR T cell therapies also express checkpoint proteins that can limit their anti-tumor activity.

Wang said Refuge designs its CARs to trigger checkpoint suppression by attaching a protease

Read the full 728 word article

How to gain access

Continue reading with a
two-week free trial.